Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Nanoviricides Inc
(NY:
NNVC
)
1.610
-0.070 (-4.17%)
Official Closing Price
Updated: 8:00 PM EDT, Sep 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nanoviricides Inc
< Previous
1
2
3
4
5
6
Next >
NanoViricides, Inc. Has Filed its Quarterly Report: Coronavirus Drug NV-CoV-2 IND Stage
November 15, 2022
Via
ACCESSWIRE
7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov.
October 28, 2022
While penny stocks are highly speculative and risky, you may still want to consider these seven opportunities.
Via
InvestorPlace
This Company Is Looking For A Monkeypox Drug As City Investigates Deaths
October 27, 2022
By David Willey, Benzinga
Via
News Direct
Topics
Death
Exposures
COVID-19
Death
This Company Is Looking For A Monkeypox Drug As City Investigates Deaths
October 27, 2022
Learn more about NanoViricides, Inc. by gaining access to the latest research report
Via
TheNewswire.com
Topics
Death
Exposures
COVID-19
Death
This Company Is Looking For A Monkeypox Drug As City Investigates Deaths
October 27, 2022
New York City is investigating the cause of death for two people who died after contracting monkeypox.
Via
Benzinga
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND Stage
October 14, 2022
Via
ACCESSWIRE
NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly
September 19, 2022
Learn More about NanoViricides, Inc. by gaining access to the latest research report
Via
TheNewswire.com
Short Volatility Alert: NanoViricides, Inc.
August 05, 2022
On Thursday, shares of NanoViricides, Inc. (NYSE: NNVC) experienced volatile short activity. After the activity, the stock price went up +48.37% to $3.65. The overall sentiment for NNVC has been...
Via
Benzinga
NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis
May 16, 2022
Via
Benzinga
NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly
September 19, 2022
By Rachael Green, Benzinga
Via
News Direct
Monkeypox Is Popping Up In Places It Shouldn't But NanoViricides Says It May Have A Solution
August 10, 2022
More than 30,000 confirmed or suspected cases of monkeypox have been reported across 93 countries in the world. While those numbers are still small scientists are now concerned that this sudden and...
Via
Benzinga
NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy
August 09, 2022
Via
ACCESSWIRE
NanoViricides Initiates New Drug Development To Combat Monkeypox Virus
August 05, 2022
NanoViricides, Inc. (NYSE American: NNVC) reports that it has begun drug development to combat the monkeypox virus.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
August 04, 2022
Good morning! It's time for another dive into the biggest pre-market stock movers as we see what's affecting shares on Thursday!
Via
InvestorPlace
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
August 05, 2022
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share...
Via
Benzinga
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session
August 04, 2022
Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.
Via
Benzinga
NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus
August 04, 2022
Via
ACCESSWIRE
NanoViricides Patents Its Antiviral Nanotechnology for COVID-19, Continuing Its Development of Potentially Broad-Spectrum Drugs That Are Expected To Be Effective Even Against Emerging Variants
May 25, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
58 Biggest Movers From Yesterday
May 24, 2022
Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its complement portfolio for $60 million.
Via
Benzinga
30 Stocks Moving In Monday's Mid-Day Session
May 23, 2022
Gainers Evolve Transition Infrastructure LP (NYSE: SNMP) shares rose 29.2% to $0.6699 after jumping around 14% on Friday.
Via
Benzinga
Mid-Morning Market Update: Markets Mixed; Broadcom In Talks To Buy VMWare
May 23, 2022
U.S. stocks traded mixed this morning, with the Dow Jones gaining around 250 points on Monday.
Via
Benzinga
24 Stocks Moving in Monday's Pre-Market Session
May 23, 2022
Gainers Genocea Biosciences, Inc. (NASDAQ: GNCA) shares rose 33.8% to $0.2795 in pre-market trading after declining around 5% on Friday.
Via
Benzinga
66 Biggest Movers From Friday
May 23, 2022
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.
Via
Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
May 22, 2022
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.
Via
Benzinga
71 Biggest Movers From Yesterday
May 20, 2022
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation...
Via
Benzinga
CDC Looking Into 180 Cases Of Unexplained Pediatric Acute Hepatitis: CNBC
May 19, 2022
The Centers for Disease Control and Prevention is now investigating 180 cases of children who suddenly developed severe hepatitis across 36 states and territories, an increase of 71 cases since the...
Via
Benzinga
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application
May 17, 2022
SHELTON, CT / ACCESSWIRE / May 17, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel...
From
NanoViricides, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis
May 16, 2022
SHELTON, CT / ACCESSWIRE / May 16, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel...
From
NanoViricides, Inc.
Via
AccessWire
Exposures
COVID-19
NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program
April 25, 2022
SHELTON, CT / ACCESSWIRE / April 25, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel...
From
NanoViricides, Inc.
Via
AccessWire
Exposures
COVID-19
Pharmaceutical Companies Are Reportedly Refocusing On Mysterious Rise In Shingles Infections As COVID Declines
March 07, 2022
Photo Credit: Photo by CDC & Klara Kulikova This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.